Development of replication-deficient adenovirus malaria vaccines

References

• Vanderberg JP. Imaging mosquito transmission of Plasmodium sporozoites into the mammalian host: immunological implications. Parasitol Int. 2014;63:150–164.
   PubMed Web of Science ®Google Scholar
• Radtke AJ, Tse SW, Zavala F. From the draining lymph node to the liver: the induction and effector mechanisms of malaria-specific CD8+ T cells. Semin Immunopathol. 2015;37:211–220.
   PubMed Web of Science ®Google Scholar
• Radtke AJ, Kastenmuller W, Espinosa DA, et al. Lymph-node resident CD8α+ dendritic cells capture antigens from migratory malaria sporozoites and induce CD8+ T cell responses. PLoS Pathog. 2015;11:e1004637.
   PubMed Web of Science ®Google Scholar
• WHO. World Malaria Report 2015. 2015. Available from: http://www.who.int/malaria/publications/world-malaria-report-2015/report/en/
   Google Scholar
• Ariey F, Witkowski B, Amaratunga C, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014;505:50–55.
   PubMed Web of Science ®Google Scholar
• Takala-Harrison S, Jacob CG, Arze C, et al. Independent emergence of artemisinin resistance mutations among Plasmodium falciparum in Southeast Asia. J Infect Dis. 2015;211:670–679.
   PubMed Web of Science ®Google Scholar
• Birkett AJ. Status of vaccine research and development of vaccines for malaria prepared for WHO PD-VAC. Vaccine. 2016;34:2915–2920.
   PubMed Web of Science ®Google Scholar
• Moorthy VS, Newman RD, Okwo-Bele JM. Malaria vaccine technology roadmap. Lancet. 2013;382:1700–1701.
   PubMed Web of Science ®Google Scholar
• Teneza-Mora N, Lumsden J, Villasante E. A malaria vaccine for travelers and military personnel: requirements and top candidates. Vaccine. 2015;33:7551–7558.
   PubMed Web of Science ®Google Scholar
• Richie TL, Billingsley PF, Sim BK, et al. Progress with Plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccines. Vaccine. 2015;33:7452–7461.
   PubMed Web of Science ®Google Scholar
• Crompton PD, Moebius J, Portugal S, et al. Malaria immunity in man and mosquito: insights into unsolved mysteries of a deadly infectious disease. Annu Rev Immunol. 2014;32:157–187.
   PubMed Web of Science ®Google Scholar
• Seder RA, Chang LJ, Enama ME, et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science. 2013;341:1359–1365.
   PubMed Web of Science ®Google Scholar
• Ishizuka AS, Lyke KE, DeZure A, et al. Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. Nat Med. 2016;22:614–623.
   PubMed Web of Science ®Google Scholar
• Stoute JA, Slaoui M, Heppner DG, et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N Engl J Med. 1997;336:86–91.
   PubMed Web of Science ®Google Scholar
• Rts SCTP. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet. 2015;386:31–45.
   PubMed Web of Science ®Google Scholar
• Krzych U, Dalai S, Zarling S, et al. Memory CD8 T cells specific for plasmodia liver-stage antigens maintain protracted protection against malaria. Front Immunol. 2012;3:370.
   PubMed Web of Science ®Google Scholar
• Frevert U, Krzych U. Plasmodium cellular effector mechanisms and the hepatic microenvironment. Front Microbiol. 2015;6:482.
   PubMed Web of Science ®Google Scholar
• Weiss WR, Jiang CG. Protective CD8+ T lymphocytes in primates immunized with malaria sporozoites. PLoS One. 2012;7:e31247.
   PubMed Web of Science ®Google Scholar
• Nganou-Makamdop K, van Gemert GJ, Arens T, et al. Long term protection after immunization with P. berghei sporozoites correlates with sustained IFNγ responses of hepatic CD8+ memory T cells. PLoS One. 2012;7:e36508.
   PubMed Web of Science ®Google Scholar
• Zarling S, Berenzon D, Dalai S, et al. The survival of memory CD8 T cells that is mediated by IL-15 correlates with sustained protection against malaria. J Immunol. 2013;190:5128–5141.
   PubMed Web of Science ®Google Scholar
• Sun P, Schwenk R, White K, et al. Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma. J Immunol. 2003;171:6961–6967.
   PubMed Web of Science ®Google Scholar
• Epstein JE, Tewari K, Lyke KE, et al. Live attenuated malaria vaccine designed to protect through hepatic CD8+ T cell immunity. Science. 2011;334:475–480.
   PubMed Web of Science ®Google Scholar
• Ewer KJ, Sierra-Davidson K, Salman AM, et al. Progress with viral vectored malaria vaccines: a multi-stage approach involving “unnatural immunity”. Vaccine. 2015;33:7444–7451.
   PubMed Web of Science ®Google Scholar
• Nahrendorf W, Scholzen A, Sauerwein RW, et al. Cross-stage immunity for malaria vaccine development. Vaccine. 2015;33:7513–7517.
   PubMed Web of Science ®Google Scholar
• Sedegah M, Hedstrom R, Hobart P, et al. Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. Proc Natl Acad Sci U S A. 1994;91:9866–9870.
   PubMed Web of Science ®Google Scholar
• Richie TL, Charoenvit Y, Wang R, et al. Clinical trial in healthy malaria-naive adults to evaluate the safety, tolerability, immunogenicity and efficacy of MuStDO5, a five-gene, sporozoite/hepatic stage Plasmodium falciparum DNA vaccine combined with escalating dose human GM-CSF DNA. Hum Vaccin Immunother. 2012;8:1564–1584.
   PubMed Web of Science ®Google Scholar
• Weiss WR, Kumar A, Jiang G, et al. Protection of rhesus monkeys by a DNA prime/poxvirus boost malaria vaccine depends on optimal DNA priming and inclusion of blood stage antigens. PLoS ONE. 2007;2:e1063.
   PubMed Web of Science ®Google Scholar
• Jiang G, Shi M, Conteh S, et al. Sterile protection against Plasmodium knowlesi in rhesus monkeys from a malaria vaccine: comparison of heterologous prime boost strategies. PLoS One. 2009;4:e6559.
   PubMed Web of Science ®Google Scholar
• Rodrigues EG, Zavala F, Nussenzweig RS, et al. Efficient induction of protective anti-malaria immunity by recombinant adenovirus. Vaccine. 1998;16:1812–1817.
   PubMed Web of Science ®Google Scholar
• Ghebremedhin B. Human adenovirus: viral pathogen with increasing importance. Eur J Microbiol Immunol (Bp). 2014;4:26–33.
   PubMedGoogle Scholar
• Bergelson JM, Cunningham JA, Droguett G, et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science. 1997;275:1320–1323.
   PubMed Web of Science ®Google Scholar
• Gaggar A, Shayakhmetov DM, Lieber A. CD46 is a cellular receptor for group B adenoviruses. Nat Med. 2003;9:1408–1412.
   PubMed Web of Science ®Google Scholar
• Colloca S, Barnes E, Folgori A, et al. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med. 2012;4:115ra2.
   PubMed Web of Science ®Google Scholar
• Quinn KM, Da Costa A, Yamamoto A, et al. Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization. J Immunol. 2013;190:2720–2735.
   PubMed Web of Science ®Google Scholar
• Tan WG, Jin HT, West EE, et al. Comparative analysis of simian immunodeficiency virus gag-specific effector and memory CD8+ T cells induced by different adenovirus vectors. J Virol. 2013;87:1359–1372.
   PubMed Web of Science ®Google Scholar
• Kemper C, Leung M, Stephensen CB, et al. Membrane cofactor protein (MCP; CD46) expression in transgenic mice. Clin Exp Immunol. 2001;124:180–189.
   PubMed Web of Science ®Google Scholar
• Sedegah M, Tamminga C, McGrath S, et al. Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults. PLoS One. 2011;6:e24586.
   PubMed Web of Science ®Google Scholar
• Tamminga C, Sedegah M, Maiolatesi S, et al. Human adenovirus 5-vectored Plasmodium falciparum NMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infection. Hum Vaccin Immunother. 2013;9:2165–2177.
   PubMed Web of Science ®Google Scholar
• Chuang I, Sedegah M, Cicatelli S, et al. DNA prime/adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity. PLoS One. 2013;8:e55571.
   PubMed Web of Science ®Google Scholar
• Sedegah M, Hollingdale MR, Farooq F, et al. Sterile immunity to malaria after DNA prime/adenovirus boost immunization is associated with effector memory CD8+T cells targeting AMA1 class I epitopes. PLoS One. 2014;9:e106241.
   PubMed Web of Science ®Google Scholar
• Creech CB, Dekker CL, Ho D, et al. Randomized, placebo-controlled trial to assess the safety and immunogenicity of an adenovirus type 35-based circumsporozoite malaria vaccine in healthy adults. Hum Vaccin Immunother. 2013;9:2548–2557.
   PubMed Web of Science ®Google Scholar
• Ouedraogo A, Tiono AB, Kargougou D, et al. A phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in Burkinabe healthy adults 18 to 45 years of age. PLoS One. 2013;8:e78679.
   PubMed Web of Science ®Google Scholar
• Ockenhouse CF, Regules J, Tosh D, et al. Ad35.CS.01-RTS,S/AS01 heterologous prime boost vaccine efficacy against sporozoite challenge in healthy malaria-naive adults. PLoS One. 2015;10:e0131571.
   PubMed Web of Science ®Google Scholar
• O’Hara GA, Duncan CJ, Ewer KJ, et al. Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J Infect Dis. 2012;205:772–781.
   PubMed Web of Science ®Google Scholar
• Ewer KJ, O’Hara GA, Duncan CJ, et al. Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat Commun. 2013;4:2836.
   PubMed Web of Science ®Google Scholar
• Elias SC, Collins KA, Halstead FD, et al. Assessment of immune interference, antagonism, and diversion following human immunization with biallelic blood-stage malaria viral-vectored vaccines and controlled malaria infection. J Immunol. 2013;190:1135–1147.
   PubMed Web of Science ®Google Scholar
• Sheehy SH, Duncan CJ, Elias SC, et al. ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. Mol Ther. 2012;20:2355–2368.
   PubMed Web of Science ®Google Scholar
• Sheehy SH, Duncan CJ, Elias SC, et al. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. PLoS One. 2012;7:e31208.
   PubMed Web of Science ®Google Scholar
• Biswas S, Choudhary P, Elias SC, et al. Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure. PLoS One. 2014;9:e107903.
   PubMed Web of Science ®Google Scholar
• Elias SC, Choudhary P, de Cassan SC, et al. Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection. Immunology. 2014;141:628–644.
   PubMed Web of Science ®Google Scholar
• Ogwang C, Afolabi M, Kimani D, et al. Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults. PLoS One. 2013;8:e57726.
   PubMed Web of Science ®Google Scholar
• Kimani D, Jagne YJ, Cox M, et al. Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations. Mol Ther. 2014;22:1992–2003.
   PubMed Web of Science ®Google Scholar
• de Barra E, Hodgson SH, Ewer KJ, et al. A phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS. PLoS One. 2014;9:e115161.
   PubMed Web of Science ®Google Scholar
• Hodgson SH, Ewer KJ, Bliss CM, et al. Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals. J Infect Dis. 2015;211:1076–1086.
   PubMed Web of Science ®Google Scholar
• Afolabi MO, Tiono AB, Adetifa UJ, et al. Safety and immunogenicity of ChAd63 and MVA ME-TRAP in West African children and infants. Mol Ther. 2016. DOI:10.1038/mt.2016.83
   PubMed Web of Science ®Google Scholar
• Ogwang C, Kimani D, Edwards NJ, et al. Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults. Sci Transl Med. 2015;7:286re5.
   PubMed Web of Science ®Google Scholar
• Hodgson SH, Choudhary P, Elias SC, et al. Combining viral vectored and protein-in-adjuvant vaccines against the blood-stage malaria antigen AMA1: report on a phase 1a clinical trial. Mol Ther. 2014;22:2142–2154.
   PubMed Web of Science ®Google Scholar
• Rampling T, Ewer KJ, Bowyer G, et al. Safety and high level efficacy of the combination malaria vaccine regimen of RTS,S/AS01B with ChAd-MVA vectored vaccines expressing ME-TRAP. J Infect Dis. 2016;214:772–781.
   PubMed Web of Science ®Google Scholar
• De Santis O, Audran R, Pothin E, et al. Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. Lancet Infect Dis. 2016;16:311–320.
   PubMed Web of Science ®Google Scholar
• Tapia MD, Sow SO, Lyke KE, et al. Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2016;16:31–42.
   PubMed Web of Science ®Google Scholar
• Churchyard GJ, Morgan C, Adams E, et al. A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204). PLoS One. 2011;6:e21225.
   PubMed Web of Science ®Google Scholar
• Frahm N, DeCamp AC, Friedrich DP, et al. Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine. J Clin Invest. 2012;122:359–367.
   PubMed Web of Science ®Google Scholar
• Bruder JT, Semenova E, Chen P, et al. Modification of Ad5 hexon hypervariable regions circumvents pre-existing Ad5 neutralizing antibodies and induces protective immune responses. PLoS One. 2012;7:e33920.
   PubMed Web of Science ®Google Scholar
• Silvie O, Franetich JF, Charrin S, et al. A role for apical membrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites. J Biol Chem. 2004;279:9490–9496.
   PubMed Web of Science ®Google Scholar
• Koup RA, Roederer M, Lamoreaux L, et al. Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses. PLoS One. 2010;5:e9015.
   PubMed Web of Science ®Google Scholar
• Reyes-Sandoval A, Wyllie DH, Bauza K, et al. CD8+ T effector memory cells protect against liver-stage malaria. J Immunol. 2011;187:1347–1357.
   PubMed Web of Science ®Google Scholar
• Sedegah M, Hollingdale MR, Farooq F, et al. Controlled human malaria infection (CHMI) differentially affects cell-mediated and antibody responses to CSP and AMA1 induced by adenovirus vaccines with and without DNA-priming. Hum Vaccin Immunother. 2015;11:2705–2715.
   PubMed Web of Science ®Google Scholar
• Fauci AS, Marovich MA, Dieffenbach CW, et al. Immunology. Immune activation with HIV vaccines. Science. 2014;344:49–51.
   PubMed Web of Science ®Google Scholar
• McVey D, Cranfield MR, Torano H, et al. Adenoviruses isolated from wild gorillas are closely related to human species C viruses. Virology. 2013;444:119–123.
   PubMed Web of Science ®Google Scholar
• Gilbert SC. T-cell-inducing vaccines – what’s the future. Immunology. 2012;135:19–26.
   PubMed Web of Science ®Google Scholar
• Schneider J, Gilbert SC, Blanchard TJ, et al. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med. 1998;4:397–402.
   PubMed Web of Science ®Google Scholar
• Schneider J, Langermans JA, Gilbert SC, et al. A prime-boost immunisation regimen using DNA followed by recombinant modified vaccinia virus Ankara induces strong cellular immune responses against the Plasmodium falciparum TRAP antigen in chimpanzees. Vaccine. 2001;19:4595–4602.
   PubMed Web of Science ®Google Scholar
• McConkey SJ, Reece WH, Moorthy VS, et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med. 2003;9:729–735.
   PubMed Web of Science ®Google Scholar
• Moorthy VS, Imoukhuede EB, Milligan P, et al. A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults. PLoS Med. 2004;1:e33.
   PubMedGoogle Scholar
• Anderson RJ, Hannan CM, Gilbert SC, et al. Enhanced CD8+ T cell immune responses and protection elicited against Plasmodium berghei malaria by prime boost immunization regimens using a novel attenuated fowlpox virus. J Immunol. 2004;172:3094–3100.
   PubMed Web of Science ®Google Scholar
• Vuola JM, Keating S, Webster DP, et al. Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers. J Immunol. 2005;174:449–455.
   PubMed Web of Science ®Google Scholar
• Webster DP, Dunachie S, Vuola JM, et al. Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc Natl Acad Sci U S A. 2005;102:4836–4841.
   PubMed Web of Science ®Google Scholar
• Walther M, Thompson FM, Dunachie S, et al. Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein. Infect Immun. 2006;74:2706–2716.
   PubMed Web of Science ®Google Scholar
• Bejon P, Kai OK, Mwacharo J, et al. Alternating vector immunizations encoding pre-erythrocytic malaria antigens enhance memory responses in a malaria endemic area. Eur J Immunol. 2006;36:2264–2272.
   PubMed Web of Science ®Google Scholar
• Gilbert SC, Schneider J, Hannan CM, et al. Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. Vaccine. 2002;20:1039–1045.
   PubMed Web of Science ®Google Scholar
• Colloca S, Folgori A, Ammendola V, et al. Generation and screening of a large collection of novel simian adenovirus allows the identification of vaccine vectors inducing potent cellular immunity in humans. Sci Transl Med. 2013;4:115ra2.
   Google Scholar
• Capone S, D’Alise AM, Ammendola V, et al. Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials. Expert Rev Vaccines. 2013;12:379–393.
   PubMed Web of Science ®Google Scholar
• Morrot A, Rodrigues MM. Tissue signatures influence the activation of intrahepatic CD8(+) T cells against malaria sporozoites. Front Microbiol. 2014;5:440.
   PubMed Web of Science ®Google Scholar
• Sheehy SH, Duncan CJ, Elias SC, et al. Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. Mol Ther. 2011;19:2269–2276.
   PubMed Web of Science ®Google Scholar
• Shekalaghe S, Rutaihwa M, Billingsley PF, et al. Controlled human malaria infection of Tanzanians by intradermal injection of aseptic, purified, cryopreserved Plasmodium falciparum sporozoites. Am J Trop Med Hyg. 2014;91:471–480.
   PubMed Web of Science ®Google Scholar
• Hodgson SH, Juma E, Salim A, et al. Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injection. Front Microbiol. 2014;5:686.
   PubMed Web of Science ®Google Scholar
• Longley RJ, Halbroth BR, Ewer KJ, et al. Identification of immunodominant responses to the Plasmodium falciparum antigens PfUIS3, PfLSA1 and PfLSAP2 in multiple strains of mice. PLoS One. 2015;10:e0144515.
   Web of Science ®Google Scholar
• Barry AE, Arnott A. Strategies for designing and monitoring malaria vaccines targeting diverse antigens. Front Immunol. 2014;5:359.
   PubMed Web of Science ®Google Scholar
• Remarque EJ, Faber BW, Kocken CH, et al. Apical membrane antigen 1: a malaria vaccine candidate in review. Trends Parasitol. 2008;24:74–84.
   PubMed Web of Science ®Google Scholar
• Douglas AD, Williams AR, Illingworth JJ, et al. The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody. Nat Commun. 2011;2:601.
   PubMed Web of Science ®Google Scholar
• Kapulu MC, Da DF, Miura K, et al. Comparative assessment of transmission-blocking vaccine candidates against Plasmodium falciparum. Sci Rep. 2015;5:11193.
   PubMed Web of Science ®Google Scholar
• Li Y, Leneghan DB, Miura K, et al. Enhancing immunogenicity and transmission-blocking activity of malaria vaccines by fusing Pfs25 to IMX313 multimerization technology. Sci Rep. 2016;6:18848.
   PubMed Web of Science ®Google Scholar
• Spencer AJ, Hill F, Honeycutt JD, et al. Fusion of the Mycobacterium tuberculosis antigen 85A to an oligomerization domain enhances its immunogenicity in both mice and non-human primates. PLoS One. 2012;7:e33555.
   PubMed Web of Science ®Google Scholar
• de Cassan SC, Shakri AR, Llewellyn D, et al. Preclinical assessment of viral vectored and protein vaccines targeting the Duffy-binding protein region II of Plasmodium vivax. Front Immunol. 2015;6:348.
   PubMed Web of Science ®Google Scholar
• Warimwe GM, Gesharisha J, Carr BV, et al. Chimpanzee adenovirus vaccine provides multispecies protection against rift valley fever. Sci Rep. 2016;6:20617.
   PubMed Web of Science ®Google Scholar
• Antrobus RD, Coughlan L, Berthoud TK, et al. Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens. Mol Ther. 2014;22:668–674.
   PubMed Web of Science ®Google Scholar
• Swadling L, Capone S, Antrobus RD, et al. A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Sci Transl Med. 2014;6:261ra153.
   PubMed Web of Science ®Google Scholar
• Radosevic K, Rodriguez A, Lemckert AA, et al. The Th1 immune response to Plasmodium falciparum circumsporozoite protein is boosted by adenovirus vectors 35 and 26 with a homologous insert. Clin Vaccine Immunol. 2010;17:1687–1694.
   PubMed Web of Science ®Google Scholar
• Baden LR, Walsh SR, Seaman MS, et al. First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001). J Infect Dis. 2013;207:240–247.
   PubMed Web of Science ®Google Scholar
• De Rosa SC, Thomas EP, Bui J, et al. HIV-DNA priming alters T cell responses to HIV-adenovirus vaccine even when responses to DNA are undetectable. J Immunol. 2011;187:3391–3401.
   PubMed Web of Science ®Google Scholar
• Wilson KL, Xiang SD, Plebanski M. A model to study the impact of polymorphism driven liver-stage immune evasion by malaria parasites, to help design effective cross-reactive vaccines. Front Microbiol. 2016;7:303.
   PubMed Web of Science ®Google Scholar
• Flanagan KL, Wilson KL, Plebanski M. Polymorphism in liver-stage malaria vaccine candidate proteins: immune evasion and implications for vaccine design. Expert Rev Vaccines. 2016;15:389–399.
   PubMed Web of Science ®Google Scholar
• Biswas S, Dicks MD, Long CA, et al. Transgene optimization, immunogenicity and in vitro efficacy of viral vectored vaccines expressing two alleles of Plasmodium falciparum AMA1. PLoS One. 2011;6:e20977.
   PubMed Web of Science ®Google Scholar
• Betts G, Poyntz H, Stylianou E, et al. Optimising immunogenicity with viral vectors: mixing MVA and HAdV-5 expressing the mycobacterial antigen Ag85A in a single injection. PLoS One. 2012;7:e50447.
   PubMed Web of Science ®Google Scholar
• Reyes-Sandoval A, Rollier CS, Milicic A, et al. Mixed vector immunization with recombinant adenovirus and MVA can improve vaccine efficacy while decreasing antivector immunity. Mol Ther. 2012;20:1633–1647.
   PubMed Web of Science ®Google Scholar
• Rollier CS, Hill AVS, Reyes-Sandoval A. Influence of adenovirus and MVA vaccines on the breadth and hierarchy of T cell responses. Vaccine [Internet]. 2016;34:4470–4474. Available from: http://dx.doi.org/j.vaccine.2016.07.050
   PubMed Web of Science ®Google Scholar
• Pearson FE, McNeilly CL, Crichton ML, et al. Dry-coated live viral vector vaccines delivered by nanopatch microprojections retain long-term thermostability and induce transgene-specific T cell responses in mice. PLoS One. 2013;8:e67888.
   PubMed Web of Science ®Google Scholar
• Pearson FE, O’Mahony C, Moore AC, et al. Induction of CD8(+) T cell responses and protective efficacy following microneedle-mediated delivery of a live adenovirus-vectored malaria vaccine. Vaccine. 2015;33:3248–3255.
   PubMed Web of Science ®Google Scholar